Suspension of the Teva marketing authorisation for Levothyroxine 100 microgram tablets

Details of the suspension of the marketing authorisation of Levothyroxine 100 microgram tablets, including MHRA investigations.



This report looks at the circumstances leading up to the suspension of this product, communications about the suspension and the outcome of Medicines and Healthcare products Regulatory Agency (MHRA) investigations immediately following the suspension.